Clinicians are urging participants in the PrEPX research study to continue their PrEP* medication, following reports that a study participant tested positive to HIV while being enrolled in the PrEPX trial.

Human clinical trials of a world-first peanut allergy treatment will begin in Melbourne next month, with researchers focussing on the molecular parts of the potent nut allergen that are needed to build tolerance, while removing the risk of a severe reaction.

Alfred ICU runs a variety of courses for health professionals, including Advanced Life Support 2 (ALS2).

This five month course will provide students with a thorough understanding of Evidence Based Medicine (EBM) and Research Methods (RM) in the emergency medicine setting.